Andrew Booth, Chief Financial Officer at AbCellera Biologics Inc.. Biography, career history and compensation sourced from SEC proxy filings.
About
Andrew Booth has served as AbCellera's Chief Financial Officer since August 2019 and previously served on the company's Board of Directors from June 2016 to August 2019, playing a key role in the company's 2020 Nasdaq IPO. Before AbCellera he spent roughly a decade at Vancouver-based STEMCELL Technologies Inc., serving as Chief Commercial Officer (2017-2019), Chief Financial Officer (2013-2017) and VP, Instrumentation (2010-2013). Earlier he spent seven years at GE, concluding as leader of M&A for GE Healthcare's EMEA and global Life Sciences businesses in London. He holds an MBA from INSEAD and a B.A.Sc. in Engineering Physics from the University of British Columbia.
Roles
AbCellera Biologics Inc.
Chief Financial Officer · Current role
August 2019–present
AbCellera Biologics Inc.
Member of the Board of Directors
June 2016 - August 2019
STEMCELL Technologies Inc.
Chief Commercial Officer
February 2017 - July 2019
STEMCELL Technologies Inc.
Chief Financial Officer
March 2013 - January 2017
GE Healthcare
M&A leader, EMEA and Life Sciences · Based in London, UK
2004 - 2009
External Roles
Aspect Biosystems
Director
—
Karius Diagnostics
Director
—
5AM Venture Capital
Advisor
—
Fixed Compensation
FY 2025
Salary
$485,000
ComponentAnnual base salary earned in FY2025 (USD)
All other compensation
$23,244
ComponentRRSP employer contributions
Total compensation
$3,382,244
Performance Compensation
Data from FY 2025
Cash incentive
Bonus
$218,567
Target Opportunity
—
PlanDiscretionary annual cash incentive bonus for 2025 (45% of base-salary target)
Stock awards
Stock options
$2,655,434
FormStock options, ASC 718 grant-date fair value (NEO long-term incentives are 100% options)